Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -75.43% is 52% below its 5-year average of -49.59%, around the middle of its 5-year range (-206.44%–-0.01%).
49.25% above its 12-month average of -148.63%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -9.66%.
RETURN ON ASSETS (ROA)
-75.43%
RETURN ON ASSETS (ROA) AVG TTM
-148.63%
RETURN ON ASSETS (ROA) AVG 3Y
-74.35%
RETURN ON ASSETS (ROA) AVG 5Y
-49.59%
RETURN ON ASSETS (ROA) AVG 10Y
-27.05%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+49.25%
CURRENT VS 3Y AVG
-1.46%
CURRENT VS 5Y AVG
-52.09%
CURRENT VS 10Y AVG
-178.84%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-133.96%
vs the sector median at left
Rein Therapeutics Inc.
Market Cap
$22.88M
Return on Assets (ROA)
-75.43%
TTM Avg
-148.63%
3Y Avg
-74.35%
5Y Avg
-49.59%
Market Cap
$23.15M
Return on Assets (ROA)
-0.58%
TTM Avg
-3.56%
3Y Avg
23.24%
5Y Avg
-18.31%
Market Cap
$22.48M
Return on Assets (ROA)
-248.63%
TTM Avg
-139.76%
3Y Avg
-97.50%
5Y Avg
-68.94%
Market Cap
$22.11M
Return on Assets (ROA)
-13.57%
TTM Avg
-12.25%
3Y Avg
-12.55%
5Y Avg
-25.19%
Market Cap
$23.96M
Return on Assets (ROA)
181.24%
TTM Avg
65.61%
3Y Avg
3.99%
5Y Avg
-7.40%
Market Cap
$21.72M
Return on Assets (ROA)
-228.73%
TTM Avg
-145.44%
3Y Avg
-152.25%
5Y Avg
-187.73%
Market Cap
$24.18M
Return on Assets (ROA)
-40.73%
TTM Avg
-51.29%
3Y Avg
-88.21%
5Y Avg
-85.48%
Market Cap
$24.54M
Return on Assets (ROA)
-116.81%
TTM Avg
-53.20%
3Y Avg
-39.87%
5Y Avg
-35.95%
Market Cap
$20.54M
Return on Assets (ROA)
-173.14%
TTM Avg
-158.95%
3Y Avg
-120.45%
5Y Avg
-102.27%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rein Therapeutics Inc. (RNTX) | $22.88M | -75.43% | -148.63% | -74.35% | -49.59% |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.15M | -0.58% | -3.56% | 23.24% | -18.31% |
| LeonaBio, Inc. (LONA)vs › | $22.48M | -248.63% | -139.76% | -97.50% | -68.94% |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.11M | -13.57% | -12.25% | -12.55% | -25.19% |
| Kyntra Bio, Inc. (KYNB)vs › | $23.96M | 181.24% | 65.61% | 3.99% | -7.40% |
| Modular Medical, Inc. (MODD)vs › | $21.72M | -228.73% | -145.44% | -152.25% | -187.73% |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.18M | -40.73% | -51.29% | -88.21% | -85.48% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.54M | -116.81% | -53.20% | -39.87% | -35.95% |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.54M | -173.14% | -158.95% | -120.45% | -102.27% |
| NextCure, Inc. (NXTC)vs › | $19.29M | -188.98% | -90.06% | -67.42% | -51.71% |
ROA
-75.4%
ROE
-487.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -206.44% |
| 2024-12-31 | -90.82% |
| 2023-12-31 | -0.01% |
| 2022-12-31 | -0.12% |
| 2021-12-31 | -0.05% |
| 2020-12-31 | -0.13% |
| 2019-12-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2015-12-31 | 0.00% |
